<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01553500</url>
  </required_header>
  <id_info>
    <org_study_id>OPBG_GLUCO_2010</org_study_id>
    <nct_id>NCT01553500</nct_id>
  </id_info>
  <brief_title>Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease</brief_title>
  <acronym>GC-NASH</acronym>
  <official_title>Study of the Efficacy and Tolerability of Glucomannan on Children Affected by NAFLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bambino Gesù Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bambino Gesù Hospital and Research Institute</source>
  <brief_summary>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions and is rapidly
      becoming the one of most common causes of chronic liver disease in children. The pathogenesis
      of NAFLD is generally considered the result of a series of liver injuries, commonly referred
      as &quot;multi-hit&quot; hypothesis. Insulin resistance and increased serum levels of free fatty acids
      (FFAs) are considered the main primary hits that lead to the excessive lipid accumulation in
      hepatocytes resulting in steatosis.

      Has been reported that a diet rich in high-viscosity fiber improves glycemic control and
      lipid profile, suggesting a therapeutic potential role in the treatment of NAFLD.

      Aim of this study is to evaluate the efficacy and tolerability of glucomannan in children
      affected by non alcoholic fatty liver disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in lipid profile</measure>
    <time_frame>6,12,18,24 months</time_frame>
    <description>Evaluation of tryglicerides, total and LDL colesterol levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in glycemic homeostasis</measure>
    <time_frame>6,12,18,24 months</time_frame>
    <description>glycemic homeostesis will be evaluated through glycemia and insulinemia basal levels and after oral glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver enzymes</measure>
    <time_frame>6,12,18,24 months</time_frame>
    <description>evaluation of liver function test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>glucomannan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>glucomannan</intervention_name>
    <description>glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)</description>
    <arm_group_label>glucomannan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>lifestyle intervention</intervention_name>
    <description>hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent by parents or legal tutor

          -  ALT levels &lt;10 ULN

          -  hyperechogenicity at liver ultrasound examination suggestive of fatty liver

          -  INR &lt; 1,3

          -  Albumin &gt; 3 g/dl

          -  total bilirubin &lt; 2,5 mg/dl

          -  no previous gastrointestinal bleeding

          -  no previous portosystemic encephalopathy

          -  normal renal function

          -  no HIV-HCV-HDV infection

          -  normal cell blood count

        Exclusion Criteria:

          -  every clinical or psychiatric disease interfering with experimentation according to
             investigator's evaluation

          -  finding of active liver disease due to other causes

          -  corticosteroids, immunosuppressive drugs or chemotherapy in the 2 months before of the
             study

          -  alcohol consumption

          -  use of drugs known to induce steatosis or to affect body weight and carbohydrate
             metabolism

          -  finding of actual or previous level of alpha-fetoprotein &gt; 50 ng/ml

          -  hepatocellular carcinoma

          -  diabetes mellitus type I
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerio Nobili, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bambino Gesù Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bambino Gesù Children's Hospital and Research Institute</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2012</study_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bambino Gesù Hospital and Research Institute</investigator_affiliation>
    <investigator_full_name>Valerio Nobili</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>(1-6)-alpha-glucomannan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

